Immune-Onc: Immune-Onc Therapeutics, Inc.: Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023

- IO-202 (anti-LILRB4) is well tolerated, with encouraging clinical responses in both monotherapy and combination therapy - - FDA granted Fast Track designation to IO-202 for the treatment of rela...